Evidence map›Paper›PMID 30460507›Full record

ReviewJournal of industrial microbiology & biotechnology2019

Searching for potent and specific antibiotics against pathogenic Helicobacter and Campylobacter strains.

Yasushi Ogasawara, Tohru Dairi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of industrial microbiology & biotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Antibacterial Strategy againstACS medicinal chemistry letters · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Yasushi OgasawaraGraduate School of Engineering, Hokkaido University, N13 & W8, Kita-ku, Sapporo, Hokkaido, 060-8628, Japan. yogasawa@eng.hokudai.ac.jp.
Tohru DairiGraduate School of Engineering, Hokkaido University, N13 & W8, Kita-ku, Sapporo, Hokkaido, 060-8628, Japan. dairi@eng.hokudai.ac.jp.ORCID http://orcid.org/0000-0002-3406-7970
Hokkaido University · JP

Funding

Japan Society for the Promotion of Science 16H06452Japan Society for the Promotion of Science 18H03937
6 · The paper itself

Abstract

Menaquinone is an obligatory component of the electron-transfer pathway in microorganisms. Its biosynthetic pathway was established by pioneering studies with Escherichia coli and it was revealed to be derived from chorismate by Men enzymes. However, we identified an alternative pathway, the futalosine pathway, operating in some microorganisms including Helicobacter pylori and Campylobacter jejuni, which cause gastric carcinoma and diarrhea, respectively. Because some useful intestinal bacteria, such as lactobacilli, use the canonical pathway, the futalosine pathway is an attractive target for development of chemotherapeutics for the abovementioned pathogens. In this mini-review, we summarize compounds that inhibit Mqn enzymes involved in the futalosine pathway discovered to date.

Indexed as

Anti-Bacterial AgentsBiosynthetic PathwaysCampylobacterCampylobacter jejuniHelicobacterHelicobacter pyloriLactobacillusNucleosidesVitamin K 2Anti-Bacterial AgentsfutalosineNucleosidesVitamin K 2BiosynthesisFutalosine pathwayInhibitorsMenaquinone

Identifiers

PMID30460507
OpenAlexW2901159037

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.